<p>Antibody–Drug Conjugates (ADCs) represent a rapidly evolving, and increasingly important frontier in targeted therapeutics, demanding specialised approaches to development and manufacturing. With a highly complex supply chain, specialist Contract Development and Manufacturing Organisations (CDMOs) play a critical role in ADC development. Increasingly, positive CDMO partnerships with sponsor companies can build competitive advantage in an increasingly innovative and competitive clinical development environment for ADCs. Carefully considered CDMO engagement strategies can be employed to deliver successful outcomes for ADC development and manufacture across the full spectrum of the development life-cycle. This commentary considers early and late-stage ADC development, focusing on the systematic optimisation, technology transfer, and gap analysis essential for robust scale-up and manufacture. Facility design requirements and process modifications are discussed in the context of scalable, cGMP-compliant manufacturing, highlighting the engineering and environmental controls necessary for the safe and efficient handling of ADCs. The discussion will offers insights into the requirements for successful ADC development and manufacture with CDMO partners, while ensuring, regulatory compliance.</p> Graphical Abstract <p></p>